temozolomide has been researched along with Acute Lymphoid Leukemia in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We present a case of a 12-year-old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ)." | 7.76 | Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. ( Hosono, A; Makimoto, A; Miyakita, Y; Momota, H; Nariata, Y; Narita, Y; Shibui, S, 2010) |
| "However, TMZ-related acute lymphoblastic leukemia is rare." | 5.40 | Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient. ( Chang, PY; Chou, KN; Lin, YC; Liu, MY, 2014) |
| "Twenty patients (16 with acute myelogenous leukemia, two with acute lymphoblastic leukemia, and two with chronic myelogenous leukemia in blastic phase) received 43 cycles of temozolomide." | 5.10 | Phase I study of temozolomide in relapsed/refractory acute leukemia. ( Ahmed, T; Baskind, P; Liu, D; Loughran, T; Seiter, K; Siddiqui, A, 2002) |
| "We present a case of a 12-year-old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ)." | 3.76 | Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. ( Hosono, A; Makimoto, A; Miyakita, Y; Momota, H; Nariata, Y; Narita, Y; Shibui, S, 2010) |
| "However, TMZ-related acute lymphoblastic leukemia is rare." | 1.40 | Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient. ( Chang, PY; Chou, KN; Lin, YC; Liu, MY, 2014) |
| "Cotreatment with methoxyamine, a base excision repair inhibitor, did not sensitize CEM-R cells to TMZ, suggesting little or no contribution of N-alkylation to TMZ-induced cytotoxicity." | 1.35 | Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance. ( Ogawa, M; Ueda, T; Yamauchi, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chou, KN | 1 |
| Lin, YC | 1 |
| Liu, MY | 1 |
| Chang, PY | 1 |
| Seiter, K | 2 |
| Katragadda, S | 1 |
| Ponce, D | 1 |
| Rasul, M | 1 |
| Ahmed, N | 1 |
| Momota, H | 1 |
| Narita, Y | 1 |
| Nariata, Y | 1 |
| Miyakita, Y | 1 |
| Hosono, A | 1 |
| Makimoto, A | 1 |
| Shibui, S | 1 |
| Ogura, M | 1 |
| Todo, T | 1 |
| Tanaka, M | 1 |
| Nannya, Y | 1 |
| Ichikawa, M | 1 |
| Nakamura, F | 1 |
| Kurokawa, M | 1 |
| Brown, CC | 1 |
| Havener, TM | 1 |
| Medina, MW | 1 |
| Auman, JT | 1 |
| Mangravite, LM | 1 |
| Krauss, RM | 1 |
| McLeod, HL | 1 |
| Motsinger-Reif, AA | 1 |
| Liu, D | 1 |
| Loughran, T | 1 |
| Siddiqui, A | 1 |
| Baskind, P | 1 |
| Ahmed, T | 1 |
| Hargrave, D | 1 |
| Bouffet, E | 1 |
| Gammon, J | 1 |
| Becker, L | 1 |
| Rutka, J | 1 |
| Baruchel, S | 1 |
| Yamauchi, T | 1 |
| Ogawa, M | 1 |
| Ueda, T | 1 |
| Deans, B | 1 |
| Tisdale, MJ | 1 |
1 review available for temozolomide and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Temozolomide may induce therapy-related acute lymphoblastic leukaemia.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioma; Humans; Neoplasms, Second Primary; Precursor | 2011 |
2 trials available for temozolomide and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Temozolomide and cisplatin in relapsed/refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Resistance | 2009 |
Phase I study of temozolomide in relapsed/refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dose-Response Relationship, Drug; Drug | 2002 |
6 other studies available for temozolomide and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Cytogenetic Analysis; Dacarbazine; | 2014 |
Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazine; Female; Frontal | 2010 |
A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification | 2012 |
Response to low dose temozolomide in radiation induced gliomatosis cerebri.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Leukemi | 2003 |
Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cadmiu | 2008 |
Antitumour imidazotetrazines XXVIII 3-methyladenine DNA glycosylase activity in cell lines sensitive and resistant to temozolomide.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Burkitt Lymphoma; Cell Line; Cell Survival; Chromato | 1992 |